Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 14 of 63 for:    Lixisenatide

Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02274740
Recruitment Status : Terminated (Sponsor decision not related to safety reasons)
First Posted : October 24, 2014
Last Update Posted : January 30, 2017
Sponsor:
Information provided by (Responsible Party):
Sanofi

Tracking Information
First Submitted Date  ICMJE October 17, 2014
First Posted Date  ICMJE October 24, 2014
Last Update Posted Date January 30, 2017
Study Start Date  ICMJE April 2015
Actual Primary Completion Date August 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 22, 2014)
Change in plasma triglycerides after 10 weeks of treatment area under-the-time concentration curve between 0 and 480 minutes (AUC0-480 min) [ Time Frame: After 10 weeks of treatment ]
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT02274740 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: October 22, 2014)
  • Change from baseline in plasma triglyceride [ Time Frame: 2 days after the basal test and after 10 weeks of treatment ]
  • Change from baseline in plasma cholesterol [ Time Frame: 2 days after the basal test and after 10 weeks of treatment ]
  • Change from baseline in APO B48 [ Time Frame: 2 days after the basal test and after 10 weeks of treatment ]
  • Change from baseline in free fatty acid levels [ Time Frame: 2 days after the basal test and after 10 weeks of treatment ]
  • Change from baseline in lipoprotein distribution [ Time Frame: 2 days after the basal test and after 10 weeks of treatment ]
  • Change from baseline in LDL oxidation [ Time Frame: 2 days after the basal test and after 10 weeks of treatment ]
  • Change from baseline in postprandial plasma glucose [ Time Frame: 2 days after the basal test and after 10 weeks of treatment ]
  • Change from baseline in insulin [ Time Frame: 2 days after the basal test and after 10 weeks of treatment ]
  • Change from baseline in C-peptide [ Time Frame: 2 days after the basal test and after 10 weeks of treatment ]
  • Change from baseline in low grade inflammation (cytokines and stress oxidative markers) [ Time Frame: 2 days after the basal test and after 10 weeks of treatment ]
  • Change in baseline coronary flow reserve to assess the effect of lixisenatide on microvascular dysfunction [ Time Frame: 2 days after the basal test and after 10 weeks of treatment ]
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
Official Title  ICMJE Effect of GLP-1 Receptors Agonist Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients
Brief Summary

Primary Objective:

To evaluate the ability of lixisenatide to modulate postprandial hyperlipidemia in particular, the effects on plasma changes in triglycerides.

Secondary Objectives:

The effect of lixisenatide on the following postprandial lipids: apolipoprotein (APO) B48; free fatty acid, lipoprotein distribution, cholesterol, and low-density lipoprotein (LDL) oxidation.

The effect of lixisenatide on chronic low-grade inflammation present in non-insulin dependent diabetes mellitus (NIDDM) and obesity.

The effect of lixisenatide on microvascular dysfunction. To evaluate the effect of lixisenatide on postprandial plasma glucose, insulin and C-peptide and glucagon.

Detailed Description Maximum study duration of approximately 2.5 months (study treatment) ± 2 days Day 0 (baseline) plus a 10-week open-label, active-controlled treatment period (Final/End-of-treatment Visit).
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Type II Diabetes Mellitus
Intervention  ICMJE
  • Drug: LIXISENATIDE AVE0010
    Pharmaceutical form:solution Route of administration: subcutaneous
  • Drug: metformin
    Pharmaceutical form:tablet Route of administration: oral
Study Arms  ICMJE
  • Experimental: lixisenatide

    Lixisenatide injection should be performed in the morning, within 1 hour (ie, 0-60 minutes), prior to breakfast (or standardized meal).

    Lixisenatide is to be started with once daily injections of 10 μg per day for 2 weeks then to be continued by the maintenance dose (8 weeks) of 20 μg/d up to the end of the treatment period.

    Interventions:
    • Drug: LIXISENATIDE AVE0010
    • Drug: metformin
  • No Intervention: metformin
    Greater than or equal than 1.5 g/day as background therapy for 10 weeks
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: August 26, 2015)
2
Original Estimated Enrollment  ICMJE
 (submitted: October 22, 2014)
36
Actual Study Completion Date  ICMJE August 2015
Actual Primary Completion Date August 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion criteria:

Male and female patients, 18-70 years of age.

Diagnosis of Type 2 diabetes treated with metformin and obesity (body mass index [BMI] >30 kg/m^2) and the following other abnormalities:

  • Abdominal obesity (waist circumference >102 cm in men and >88 cm in women). According to National Cholesterol Education Program-Adult Treatment Panel (NCEP-ATP) III (2001).
  • Glycated hemoglobin A1c (HbA1c) ≥7 and ≤8.5% (after Sponsor approval providers might reasonably suggest more stringent A1c goals [such as 6.5%] for selected individual patients, if this can be achieved without significant hypoglycemia or other adverse effects of treatment. Appropriate patients might include those with short duration of diabetes, long life expectancy, and no significant cardiovascular disease).
  • Hypertriglyceridemia (fasting triglyceride levels between 150 mg/dL and 600 mg/dL, cholesterol <300 mg/dL. In order to exclude patients who might be suffering from a primitive dyslipidemia).
  • Low high-density lipoprotein (HDL) cholesterol (serum HDL-cholesterol <40 mg/dL in men and <50 mg/dL in women).

Written informed consent.

Exclusion criteria:

Smoking. Thyroid disease even if under appropriate hormonal replacement therapy or thyroid suppressant (Thyroid Stimulating Hormone [TSH] >5 mU/L with clinical symptoms of hypothyroidism).

Hepatic disease (Aspartate Aminotransferase [ASAT] or Alanine Aminotransferase [ALAT] >2 times the upper limit of normal).

Renal disease (serum creatinine >1.7 times the upper limit of normal). A history of coronary heart disease, cerebrovascular disease, or peripheral arterial disease in the 6 months before enrollment.

History of malignancies. Use of lipid lowering therapy. Systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg. Triglycerides >600 mg/dL. History of chronic pancreatitis or of idiopathic acute pancreatitis.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02274740
Other Study ID Numbers  ICMJE LIXISL07016
U1111-1153-3774 ( Other Identifier: UTN )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Sanofi
Study Sponsor  ICMJE Sanofi
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Clinical Sciences & Operations Sanofi
PRS Account Sanofi
Verification Date January 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP